Nicolas Barthelemy, Carlos Paya
Fluidigm said this week that it has appointed Nicolas Barthelemy and Carlos Paya to its board of directors. Barthelemy most recently served as president and CEO of molecular diagnostics firm Biotheranostics. He previously served as president of global commercial operations at Life Technologies and has also led the firm's cell systems division. He also serves on the board of directors of Repligen. Paya is president, CEO, and director of immunotherapy firm Immune Design. He formerly served as president of pharmaceutical firm Elan, and was VP of Lilly Research Laboratories.